[Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux
J P
JP
CHU de Rennes, Laboratoire de parasitologie-mycologie, 1, rue Henri-le-Guilloux, 35000 Rennes, France.
Marty
P
P
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000284:Administration, Oral; D000293:Adolescent; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007893:Leishmania donovani / Q000187:drug effects; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D011247:Pregnancy; D013997:Time Factors
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine